Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- 57 Potential Risk of Tumour Lysis Syndrome with Sorafenib April 25, 2025
- 56 Safety Alert of Risk of persistent corneal with Chlorhexidin April 25, 2025
- Recall Alert: SUBSTANDARD PRODUCTS DECLARED BY DRUG TESTING LABORATORIES. April 25, 2025
- Expressions of Interest (EOI) for shortlisting of expert members of Central Licensing Board of DRAP April 24, 2025
- Prequalification Document for Vendors/Firms through EPADS for the Supply of Services for Repair & Maintenance Work April 24, 2025
- Decisions of 78th Meeting of the Medical Device Board April 23, 2025
- Rapid Alert: CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS April 22, 2025
- DRAP-PSW Gateway: Online application for Pharmaceutical export certificates April 21, 2025
- Bidding Document for Appointment of Tax Consultant April 21, 2025
- ADVISORY TO THERAPEUTIC GOODS MANUFACTURERS: MEASURES TO PREVENT DEG/EG CONTAMINATION IN ORAL LIQUID PREPARATIONS April 21, 2025
Leadership
- Nadeem Mahbub
Secretary, Ministry of NHSR&C - Dr. Obaidullah
Chief Executive Officer, DRAP

E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click Here to Register an account for following online services. Online Challan & Fee Submission fee.dra.gov.pk Commercial Import & Export

Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and

Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and

Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public

Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,

Medicine Availability
The Drug Regulatory Authority of Pakistan (DRAP) is committed to safeguard public health by ensuring the consistent availability of safe, efficacious, and quality medicines nationwide. Recognizing the critical impact of drug shortages, particularly of essential and lifesaving medicines, on patient
eApp and centralized Case Management System
We are delighted to announce that DRAP has enabled eApp for Drug Licensing & Registration application submissions. Moreover, we have introduced centralized Case Management System in the same portal for enhanced efficiency and transparency.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.